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1. Introduction 
Glioblastoma is the most aggressive, invasive and malignant type of glioma : a tumor which 
arises from the glial cells in the brain (Wrensch et al., 2002). Glioblastoma represents 54% of 
all the gliomas and 18% of all brain tumors (CBTRUS, 2011). It is the frequently occurring 
brain tumor in humans. Patients with glioblastoma usually survive 12-15 months or less 
after diagnosis. (Krex et al., 2007; Chandana et al., 2008). 
Because prognosis for patients with glioblastoma is abysmal and current therapies for the 
disease are ineffective, this review critically evaluates the current chemotherapeutic status of 
glioblastoma and highlights the need for new therapeutic targets and approaches. The 
ultimate goal is to improve the outcome of glioblastoma patients.  
2. Glioblastoma biology 
The incidence of glioblastoma peaks with increasing age and affects adults of ages 50 to 70 
(Wrensch et al., 2002). Multiple genetic mutations, upregulation or amplification of genes 
contribute to glioblastoma carcinogenesis. Depending on the aberrant signaling pathways 
involved, glioblastoma can develop either as a primary or a secondary tumor (Kleihues & 
Ohgaki , 1999; Ohgaki & Kleihues, 2007). Primary glioblastoma (representing >60% of all 
glioblastoma cases) frequently occurs in adults/older patients as a single step 
transformation with no clinical background. Genetic changes in primary glioblastoma 
include Epidermal Growth Factor Receptor overexpression (50-60%), mutations in PTEN 
(30%) and amplification of mdm2 gene. Secondary glioblastoma arises from a slowly 
progressing low grade astrocytoma or anaplastic astrocytoma to a malignant glioblastoma 
and affects the young population. Secondary glioblastoma patients survive longer than 
those with primary glioblastoma multiforme: genetic hallmark of the former group includes 
Tp53 inactivation (>60%) and overexpression of PDGF ligand and/or receptor. Primary and 
secondary glioblastomas share similar morphologies, rendering them indistinguishable 
(Kleihues & Ohgaki , 1999; Ohgaki & Kleihues, 2007).  
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3.Current therapies 
3.1 Carmustine 
Carmustine (BCNU) was the first tested and approved drug for treating glioblastoma: it 
showed modest improvement in patient survival in 1960s (Levin, 1999). Belonging to the 
class of nitrosoureas, it alkylates the O6-guanine position in the DNA and cross-links the 
DNA, thereby inhibiting cancer growth (Reithmeier et al., 2010). Carmustine is a lipophilic 
drug and crosses the blood-brain barrier (Louis et al, 2007). After being approved by FDA in 
1977, it has been the mainstay of adjuvant therapy for glioblastoma (Salvati et al., 2009). 
When glioblastoma patients were treated with carmustine after radiation therapy, their 
survival improved (Brandes et al., 2004). Many still ongoing preclinical and clinical studies 
have also tested carmustine in combination with other chemotherapeutic drugs (Silvani et 
al., 2009; Reardon et al., 2004). In 2009, a study comparing temozolomide and carmustine in 
glioblastoma indicated that carmustine was more toxic than temozolomide alone though 
both had comparable efficacy (Vinjamuri et al., 2009). Combination therapies with receptor 
tyrosine kinase inhibitors like genistein, tryphostin and carmustine were synergisitic (Liang 
& Ullyatt 1998; Khoshyomn et al., 2002). Despite its use as a mainstay therapy, the survival 
rates of patients on carmustine alone are quite low. Short half-life, chemo-resistance, high 
systemic toxicity, and difficult delivery to target site, limits carmustine’s effectiveness in 
treating glioblastoma (Johannessen et al., 2008). 
3.2 Gliadel wafers 
Gliadel wafers are biodegradable polymers loaded with carmustine, approved for treating 
recurrent glioblastoma (Panigrahi et al., 2011; Aoki et al., 2007). After glioblastoma is 
surgically removed, the wafers are implanted in its cavity. As the polymer is degraded, it 
releases the drug slowly (Panigrahi et al., 2011). In 1995, gliadel wafers showed promises 
because of their local action and high doses of loaded drug delivered to the target site with 
few off-target effects (Brem et al., 1995). Gliadel-treated patients showed median survival of 
7.2 months compared to 5.4 months in the placebo group. In 2003, a randomized, placebo-
controlled, multicenter, multi-national, double-blind phase 3 trial demonstrated a higher 
survival to risk ratio in glioblastoma patients treated with gliadel wafers, with a median 
survival rate of 13.9 months compared to 11.6 months in placebo controls (Westphal et al., 
2003). An ongoing study adopts a multimodality approach of using gliadel wafers with 
other chemotherapies in glioma patients who have undergone surgery (McGirt et al., 2009). 
Gliadel wafer with temozolomide increased the median survival of patients with newly 
diagnosed glioblastoma to 21 months (McGirt et al., 2009). Although beneficial, the use of 
gliadel wafers for intracranial treatment of glioblastoma is complicated by edema, seizures, 
post-operative infections, and hydrocephalus (Gallego et al., 2007; Weber & Goebel, 2005): 
the complications versus benefits merits re-evaluation.  
3.3 Cisplatin 
In 1965, Barnet Rosenberg et al discovered inhibition of E. coli cell division by a platinum 
compound (i.e., cisplatin) formed in electrolysis of platinum electrodes (Rosenberg et al, 
1965). Cisplatin was soon employed as an anticancer agent (Rosenberg et al, 1969; Williams, 
J.M.A Whitehouse, 1979). Cisplatin is a platinum complex with two chloride atoms and two 
amine groups positioned in a cis configuration. Once inside the body, the two chloride 
atoms are displaced by water molecules, the resulting hydrated complex crosslinks with 
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DNA strands, triggering programmed cell death (C.J. Williams, J.M.A Whitehouse, 1979). In 
1980’s cisplatin’s efficacy on brain tumor was evaluated (Stewart et al, 1982). Although 
combination therapy of cisplatin with carmustine and radiation therapy was successful, 
patients on cisplatin therapy (with or without carmustine) developed ocular and orbital 
toxicities (Miller et al., 1985). Numerous other clinical trials evaluating the effectiveness of 
cisplatin chemotherapy in glioblastoma have demonstrated few benefits. Combination of 
cisplatin with temozolomide, etoposide, thalidomide, or tyrosine kinase inhibitors as a 
treatment option for glioblastoma have also been studied but have not significantly 
increased patient survival (Silvani et al., 2004; Lassen et al., 1999; Murphy et al., 2007; 
Nagane et al., 2007). Additionally, a phase three trial of cisplatin and carmustine 
administered concurrently with radiation therapy did not have significant improved 
outcome as compared to carmustine alone and radiation therapy (Buckner et al., 2006). 
3.4 Temodar 
A drug of interest since 1990, temozolomide constitutes the first line chemotherapy for 
treating glioblastoma following surgery and radiation (Villano et al., 2009). It is an oral 
alkylating agent that adds a methyl group to the O6 position of guanine residue of the DNA: 
the resulting methylated adduct induces apoptosis (Villano et al., 2009; Malcolm et al., 2002; 
Roos et al., 2007). Being lipid soluble, temzolomide shows good bioavailability and readily 
crosses the blood-brain barrier. In 2005, a breakthrough study demonstrated a regimen of 
radiation therapy followed by adjuvant and concomitant temozolomide treatment 
prolonged survival of glioblastoma patients compared to patients treated with radiation 
alone (Stupp et al., 2005). Since then it has become a standard therapy for glioblastoma with 
or without modifications. Combination chemotherapies of temozolomide and other drugs 
are in various phases of clinical trials but none showed benefits compared to temozolomide 
treatment alone (Ren et al., 2009). One of the major drawbacks of temozolomide therapy is 
recurrence of glioblastoma. The lesion produced in the DNA by temozolomide could be 
corrected by the repair enzyme O6 methyl guanine DNA methyl transferase, encoded by the 
MGMT gene (Sarkaria et al., 2008). Response rates to temozolomide therapy depend on the 
transferase activity and cancers with high levels of MGMT activity gradually acquire 
resistance to temozolomide (Nagane et al., 2007). The promoter methylation status of 
MGMT governs a drug’s efficacy towards the tumor. Patients with an increased % of MGMT 
methylation respond more favorably to temozolomide treatment (Hegi et al., 2008). Drugs 
mimicking this enzyme are being tested in combination with temozolomide to prevent 
MGMT actions. One such drug is O6 benzylguanine, which acts as a pseudo-substrate to 
MGMT enzyme (Kaina et al., 2010; Dolan & Pegg, 1997). However, due to its dose-related 
hematologic toxicity, its use in combination with alkylating agents is still under 
investigation (Dolan & Pegg, 1997; Quinn et al., 2009). A recent study showed that patients 
with unmethylated MGMT tumors benefitted from the combination of interferon ┚ and 
temozolomide, as compared to patients who received temozolomide alone, highlighting the 
role of interferon ┚ and also suggesting that methylation status of MGMT is not a sole 
parameter controlling treatment outcome (Motomura et al., 2011). Tumor resistance to 
temozolomide as with other alkylating agents is a common phenomenon seen in patients 
with glioblastoma. Apart from MGMT, many studies have shown that resistance to 
temozolomide is mutlifactorial (Sarkaria et al., 2008). Strategies to overcome this resistance 
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have been analyzed in order to improve temozolomide’s activity against glioma and other 
cancers ( Sarkaria et al., 2008; Tentori & Graziani , 2002). With greater understanding of 
diverse mechanisms responsible for imparting resistance to cancer cells and the role played 
by growth factor receptors in glioblastoma tumorigenesis, new therapies in combination 
with temozolomide are being evaluated. Such combination therapies include use of protein 
tyrosine/serine-threonine kinase inhibitors and temozolomide (Chaponis et al., 2011; 
Guillard et al., 2009; Peereboom et al., 2010). Though some studies demonstrated beneficial 
effects, others have reported greater toxicity. Thus, as a promising drug for treating 
glioblastoma, temozolomide only modestly enhances patient survival. There is a need to 
find other small molecules with efficacy and safety profiles superior to those of current 
therapies to be targeted to glioblastoma therapy. 
4. Potential drug targets and new therapies 
4.1 Epidermal growth factor receptor (EGFR) and cellular signaling pathways 
EGFR plays a critical role in cancer progression and invasion. Present in all germ layers, EGFR 
is activated by several ligands including EGF. Binding of EGF results in homodimerization 
and/or heterodimerization with other members of the EGFR family (HER2, HER3 and HER4), 
leading to tyrosine phosphorylation of its cytoplasmic domain. This activation initiates a series 
of signaling pathways resulting in cell division. In cancer cells, mutations or amplification of 
EGFR leads to uncontrolled cell proliferation (Yarden, 2001). Activation of EGFR leads to 
activation of downstream elements such as phosphatidylinositol-3 kinase (PI3K), which 
converts phosphatidylinositol diphosphate (PIP2) to phosphatidylinositol triphosphate (PIP3). 
Protein kinase B or AKT binds the PIP3 with the pleckstrin homology (PH) domain, resulting 
in phosphorylation of AKT at threonine 308 and serine 473 sites. Phosphorylated AKT leads to 
cell growth, motility and proliferation by activating several downstream signaling pathways 
(Chakravarti et al., 2004).  
PTEN/MMAC/TEP-1, (Phosphatase and tensin homologue deleted on chromosome 
ten/mutated in multiple advanced cancer/Transforming growth factor  regulated and 
epithelial cell enriched phosphatase) a tumor suppressor gene located on chromosome 10 is 
mutated in gliomas. PTEN dephosphorylates PIP3 to PIP2 in the PI3 kinase pathway and acts 
as a negative regulator of this pathway (Cheng & Nicosia, 2001). Continuous activation of 
PI3K/Akt pathway is associated with malignant transformation of cells. Activation of PI3K 
pathway and mutations in PTEN occur frequently in GBM tumors when compared to non-
GBM tumors (Chakravarti et al., 2004).Mammalian target of rapamycin (mTOR) is a 
serine/threonine kinase known to function downstream of PI3K/Akt pathway. Akt activates 
mTOR through inhibition of TSC1/2 complex and activation of Ras homologue-enriched in 
brain (Rheb). mTOR regulates translation initiation through two pathways – eukaryotic 
translation initiation factor (eIF4E) binding proteins (4EBP1) and ribosomal p70 S6 kinase 
(p70S6K) (Hay & Sonenberg, 2004).Inhibition of signaling pathways generated by activation of 
EGFR are important targets to develop new drugs for the treatment of glioblastoma because 
EGFR is amplified and overexpressed in such tumors (Lo, 2010; Penar et al., 1997).  
4.2 PLCγ1 
Phospholipase C gamma one (PLC┛1) is an enzyme important in cell signaling. In its 
phosphorylated active form, it cleaves the membrane phospholipid, phosphatidylinositol 4, 
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5 biphosphate (PIP2) to diacylglycerol (DAG) and inositol triphosphate (IP3). IP3 increases 
intracellular calcium stores. DAG together with calcium activates protein kinase C which 
further participates in signal transduction pathways (Kim et al., 2000). Growth factor 
receptor activation is an important mediator of PLC┛1 phosphorylation and functioning. 
Overexpression of epidermal growth factor receptors (EGFR) in glioblastoma multiforme 
(GBM) promotes PLC┛1 activation (Chen et al., 1994; Yang et al., 1994; Wahl et al., 1992). 
Many functions attributed to PLC┛1 activation include proliferation, differentiation, cell 
motility and invasion of tumor cells (Jones et al., 2005; Wells & Grandis, 2003). Furthermore, 
PLC┛1 is associated with breast cancer metastasis and is highly expressed in breast cancer 
tissues (Arteaga et al., 1991). Activation of PLC┛1 by tyrosine kinase receptors mediates 
actin cytoskeleton rearrangement, through release of actin modifying proteins gelsolin, 
profilin, myosin type I (Chen et al., 1996). In the resting state, these proteins are bound to 
PIP2 and participate in cell motility only when they are released during hydrolysis of PIP2 
by PLC┛1. Thus, this mechanism defines the role played by the enzyme in cell motility and 
invasion (Chen et al., 1996). Molecular inhibition of PLC┛1 is associated with decreased 
invasion in gliomas, prostate, breast and bladder carcinomas (Turner et al., 1997; Katterle et 
al., 2004; Khoshyomn et al., 1999). A chemical inhibitor of PLC┛1, U73122 inhibits invasion 
of glioblastoma cells into co-cultured fetal rat brain aggregates (Khoshyomn et al., 1999). 
During invasion, tumor cells undergo a series of steps to proliferate and thrive locally 
(Tysnes & Mahesparan, 2001). Thus, these functional considerations of the role of PLC┛1 in 
glioblastoma proliferation and invasion strongly suggest PLC┛1 could be a drug target. 
4.4 Invasion 
The characteristic feature of glioblastoma, which makes it a lethal disease, is its propensity 
to invade surrounding normal brain tissues (Giese et al., 2003). Unlike other cancers, 
glioblastoma does not metastasize to distinct organs but infiltrates peritumoral regions 
(Giese et al., 2003; Nakada et al., 2007). Glioblastoma patients show poor survival because of 
the inability of current therapies to control the aggressively invasive glioblastoma, which is 
spurred on by autocrine and paracrine factors released from the tumor and its 
microenvironment, respectively (Hoelzinger et al., 2007). Overexpression and activity of the 
epidermal growth factor receptors in almost all glioblastomas is responsible for signaling 
pathways leading to invasion (Guillamo et al., 2009). These signals help the cancer cells to 
detach from the bulk of the tumor and adhere to the extracellular matrix components of 
other cells. The latter process follows only when the tumor invades through the matrix to 
the surrounding brain parenchyma. Thus, during invasion, a family of proteases known as 
the matrix metalloproteases and urokinase plasminogen activator receptor system play an 
active role (VanMeter et al., 2001; Mohanam et al., 2001). Being soluble zinc-dependent 
enzymes and secreted as inactive zymogens (pro-MMPs) (Visee & Nagase, 2003), matrix 
metalloproteases (MMPs) cleave the basement membrane and extracellular matrix 
components like collagen, fibronectin, laminin, and vitronectin. They help in tissue 
remodeling, angiogenesis, and metastasis (VanMeter et al., 2001). Out of the 24 members in 
the MMP family, only two forms are overexpressed in glibolastoma and their expression 
correlates with the degree of malignancy and poor survival rate (Deryugina et al., 1997; 
Choe et al., 2002). These two forms are MMP-2 (72 kDa type IV collagenase or gelatinase A) 
and MMP-9 (92 kDa type IV collagenase or gelatinase B) and differ from other members in 
their substrate preference. Some metalloproteases are not secreted but are expressed on the 
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surface of tumor cells. MT1-MMP (membrane bound matrix metalloprotease-1) is one such 
protease which is upregulated in glioblastomas. A major role of MT1-MMP is in the 
cleavage of pro-MMPs to active MMPs at the cell surface. Together with MMP-2, and MMP-
9, MT1-MMP imparts an invasive phenotype to glioblastoma multiforme (Fillmore et al., 
2001; Nakada et al., 2001). Urokinase plasminogen activator and receptor (uPA/uPAR) 
system is important in cancer cell migration and invasion (D'Alessio & Blasi, 2009; Duffy, 
2004). Once this system is activated, it converts the inactive plasminogen to the active 
plasmin. Plasmin degrades the extracellular matrix components (D'Alessio & Blasi, 2009). 
Increased expression of uPAR on the surface of glioblastoma correlates with poor prognosis. 
In contrast with normal brain tissue, high grade gliomas (i.e., glioblastoma) exhibit 
increased activity of the uPA/uPAR system (Mohanam et al., 1998; MacDonald et al., 1998). 
This system can also activate cell proliferation pathways by interacting with other proteins 
like vitronectin and integrins (Sidenius & Blasi, 2003).Many studies and clinical trials are 
now focusing on anti-invasive chemotherapies as a treatment option for glibolastoma. Apart 
from synthetic derivatives, natural compounds in soy, curcumin can also inhibit 
glioblastoma invasion in vitro (Puli et al., 2006; Senft et al., 2010). Their activity in vivo 
warrants further research. Since a vast signaling network is aberrant in glioblastoma, 
therapies directed toward a single target cannot be expected to lead to positive outcomes. 
For example, one clinical trial showed marimastat to be ineffective in increasing survival of 
patients post-radiosurgery (Levin et al., 2006). Consequently, combination therapies 
targeting invasion and other pathways in glioblatoma are still ongoing.  
4.5 Angiogenesis 
Angiogenesis, the process of formation of new blood vessels from existing blood capillaries, 
is one major contributor to glioblastoma multiforme carcinogenesis and helps the tumor 
cells to flourish (Tate & Aghi, 2009). To maintain the demand of food, nutrients, and oxygen, 
tumor cells recruit new blood vessels from those already present (Folkman, 1971; Tate & 
Aghi, 2009). Likewise, malignant gliomas are highly vascularised and have an angiogenic 
phenotype (Jain et al., 2007). Angiogenesis takes place with the over-expression of 
angiogenic factors or when the angiogenic imbalance strikes. One growth factor involved is 
vascular endothelial growth factor (VEGF), which promotes formation of endothelium in 
normal cells (Kargiotis et al., 2006). In glioblastoma, VEGF-a, a pro-angiogenic factor from 
the VEGF family, plays a crucial role in angiogenesis. VEGF-a is secreted in large amounts 
by glioblastoma cells and can elicit responses like extracellular matrix degradation, 
endothelial cell proliferation, and expression of other angiogenic factors such as urokinase 
type plasminogen activator, plasminogen activator inhibitor-1 and matrix metalloproteases 
(Plate et al., 1992). Secreted VEGF stimulates angiogenesis by binding to specific tyrosine 
kinase VEGF receptors on endothelial cells of blood vessels surrounding the tumor and 
initiates proliferation of endothelial cells, thereby ensuring the metabolic demands of the 
growing tumor are adequately met. There are other pro-angiogenic factors like 
angiopoetins, IL-8, hepatocyte growth factors, endothelins that are expressed by 
glioblastoma cells when the “angiogenic switch” is turned on: all these factors have 
functions similar to that of VEGF in promoting angiogenesis (Argyriou et al., 2009). Some 
new treatment strategies for GBM include targeting VEGF/VEGF receptors (VEGFR) by 
monoclonal antibody or VEGFR traps, respectively (Beal et al., 2011). Approved by FDA in 
2009 for treating recurrent glioblastoma, bevacizumab (Avastin) is a humanized monoclonal 
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antibody against VEGF-a (Beal et al., 2011). Bevacizumab decreases tumor blood vessel 
density and remodels tumor vasculature in a neuroblastoma xenograft model (Dickson et 
al., 2007). The National Cancer Comprehensive Network recommends bevacizumab with or 
without other chemotherapy in case of glioblastoma recurrence (National Comprehensive 
Cancer Network clinical practice guidelines in oncology-central nervous system cancers. 
v.1.2010). Combination chemotherapy of bevacizumab with irinotecan shows favorable 
results in phase 2 trials of recurrent malignant glioma (Vredenburgh et al., 2007). Clinical 
trials are on-going for using bevacizumab in new cases of glioblastoma (Lai et al, 2010). 
Inclusion of anti-angiogenic therapies to cancer treatment is favorable, because they 
facilitate increased penetration of conventional chemotherapies and show better response 
rates (Jain, 2001). Other than bevacizumab, anti-angiogenic agents in various phases of 
clinical trials include cediranib, cilengitide, and aflibercept (Batchelor et al., 2010; Reardon et 
al., 2008; Wachsberger et al., 2007). Though favorable responses and anti-tumor effects occur 
with combination of various anti-angiogenic agents in different cancer models, efficacy of 
bevacizumab monotherapy in increasing glioblastoma patient survival has not transpired. 
Emergence of an invasive phenotype while angiogenesis is being targeted in glioblastoma 
constitutes a major limitation of anti-angiogenic monotherapies (Lamszus et al., 2003; 
Verhoeff et al., 2009; Keunen et al., 2011). Thus, improved therapies need to be developed to 
target glioblastoma. 
4.6 Metabolism 
Metabolic and other functional roles of astrocytes under physiological conditions: In 
mammalian nervous system, neurons and astrocytes are intimately and functionally 
interrelated: astrocytes play key roles in neurotransmitter and substrate cycling in 
conjunction with neurons (Chowdhury et al., 2007; Hertz et al., 2007). Moreover, astrocytes 
protect neurons against various pathophysiological assaults (e.g., oxidative stress, ammonia 
toxicity) (Dukhande et al., 2006; Wong et al., 2010). However, to what extent these 
physiological roles are still assumed by astrocytes once they are transformed into 
astrocytomas has not been elucidated. Nevertheless, recent new evidence suggests that 
cancer cells, and to a lesser known extent astrocytomas too, exhibit metabolic adaptation 
and other phenotypic alterations that allow them to survive, proliferate, and invade into 
their surrounding space occupied by normal cells/tissues (Bhardwaj et al., 2010; Lino & 
Merlo, 2009; Ordys et al., 2010; Semenza, 2011; Stegh et al., 2008).  
Metabolic adaptation and/or reprogramming in cancer cells in general and 
astrocytoma/glioblastoma in particular: As early as the 1920’s, Otto Warburg and his 
associates were the first to note that cancer cells appear to depend on glycolysis for energy 
production and survival even though oxygen is not in short supply. (Warburg et al., 1927). 
Warburg’s extensive investigation into the metabolic characteristics of multiple types of 
cancer cells prompted him to hypothesize that cancer cells reply on glycolysis for energy 
supply because their mitochondrial oxidative metabolism is dysfunctional (Warburg, 1956). 
His hypothesis has been neglected for some 80 years until the recent resurgence of interests 
in “the role metabolic reprogramming in cancer progression” (Semenza, 2011). The recent 
“renaissance of the Warburg Hypothesis” (Warburg et al., 1927, Warburg, 1956) has 
stimulated a new era in elucidating the aggressive nature of many malignant tumors 
(including glioblastoma) and their purported dependence on glycolysis for energy and 
survival (Bhardwaj et al., 2010; Lino & Merlo, 2009; Ordys et al., 2010; Semenza, 2011; Stegh 
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et al., 2008). While numerous studies have documented mutations in mitochondrial DNA 
(mtDNA) in a variety of cancers (Czarnecka & Bartnik, 2009) can thus tentatively provide a 
mechanistic connection to dysfunctional mitochondrial oxidative metabolism as predicted 
by the Warburg hypothesis, other recent evidence suggests this aspect of the Warburg 
hypothesis requires critical re-appraisal (Bayley & Devilee, 2010; Dang et al., 2011; Frezza et 
al., 2011; Ordys et al., 2010; Srivastava & Moraes, 2009). 
The aspect of the Warburg hypothesis emphasizing dysfunctional mitochondrial oxidative 
metabolism in cancer cells deserves a critical re-appraisal because recent studies on cancer 
cell metabolism have uncovered new mechanistic roles for mTOR and p53. These 
mechanistic roles are new additions to the already established role of mTOR in tumor 
development and progression and the fact that in over 50% of the cancer types, p53, a 
tumor-suppressor, is mutated and their p53 mutation is associated with either decreased 
apoptosis and/or enhanced proliferation potential in those cancers. Earlier, we have already 
discussed the importance of these two phenotypic characteristics of glioblastoma.  
mTOR complex 1 (mTORC1) is aberrantly activated in many human cancers thereby 
positioning it to modulate on metabolic changes common to cancer cells (Yecies & Manning, 
2011). Furthermore, recent characterization of the metabolism of cancer cells reveals that, 
mTORC1 activation is adequate to promote an increase in glucose uptake, glycolysis, and 
lipid synthesis in addition to the pentose phosphate shunt pathway (Ramanathan & 
Schreiber, 2009; Yecies & Manning, 2011). Because these are all metabolic phenotypes of 
cancers, mTORC1 has emerged as a central relay for various oncogenic signaling pathways 
and their convergence in regulating metabolism in cancer cells (Yecies & Manning, 2011). 
The finding that mTOR functions as a positive regulator of hypoxia-inducible factor 1 (HIF-
1) activation by hypoxia (Hudson et al., 2002) highlights the importance of mTOR in 
regulating signals that lead mammalian cells, especially cancer cells, to adapt to oxygen- and 
nutrient-poor environments. Furthermore, mTOR is known to exert a direct control of 
mitochondria (Ramanathan & Schreiber, 2009). Thus, these new mechanistic roles of mTOR 
strengthen the notion we have discussed earlier that mTOR exhibits good potential as a 
target for new anti-cancer drug discovery. There has been increasing evidence 
demonstrating that p53 can regulate multiple metabolic pathways. p53 contributes to the 
regulation of glycolysis, oxidative phosphorylation, glutamine catabolism, synthesis of 
nucleotides, fatty acid oxidation, insulin sensitivity, mitochondrial integrity, antioxidant 
response, autophagy, and mTOR signaling (Maddocks & Vousden, 2011). Inactivation of 
p53 in cancer cells promotes the Warburg effect as p53 suppresses glycolysis and promotes 
oxidative phosphorylation. However, there are some known but complex cross-talks 
between the signaling pathways regulated by mTOR and p53 (Maddocks & Vousden, 2011): 
nevertheless, whether the interactions between mTOR and p53 signaling favor glioblastoma 
cell growth and proliferation remains to be fully elucidated.  
Some recent cancer cell metabolism studies have further challenged the reliance of cancer 
cells on glycolysis for energy production and lipid synthesis: in fact, such studies have 
argued that glycolysis alone is inadequate to maintain the metabolic needs of growing and 
actively dividing cancer cells (Dang et al., 2011; Maddocks & Vousden, 2011; Shanware et 
al., 2011). Thus, many researchers have re-discovered the importance of glutamine in 
meeting the inadequacy of glycolysis to fuel growth and proliferation of many cancer types 
including gliomas (Dang et al., 2011; Maddocks & Vousden, 2011; Shanware et al., 2011). In 
this context, as alluded to above, neuroscientists have long recognized the importance of 
glutamine in astrocytic metabolism and astrocytes-neurons metabolic and neurotransmitter 
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cycling (Chowdhury et al., 2007; McKenna, 2007). Consequently, these recent interests in the 
role of glutamine in cancer cell metabolism call into question the need to better appreciate 
the metabolic and neurotransmitter cycling roles of glutamine in glioblastomas. Because 
these roles in glioblastomas are poorly understood, these knowledge gaps prompted us to 
consider the appropriate techniques and approaches to allow the acquisition of this 
knowledge. Indeed, the recent rapid advances in magnetic resonance imaging (MRI) and 
nuclear magnetic resonance (NMR) spectroscopy provide exciting new possibilities in this 
area of research and development.  
Technological advances that can be exploited to diagnose and/or treat glioblastoma:MRI 
and other imaging techniques in diagnosing glioblastoma: Recent advances in magnetic 
resonance imaging (MRI) and related imaging techniques have opened new possibilities in 
the differential and more accurate clinical assessment of brain tumors including 
glioblastomas (Cha, 2009; Lemort et al., 2007; Wang & Lam, 2008). Historically, uses of MRI 
in the diagnosis of brain tumors were initially focused on neuromorphological 
demonstration, confirmation, and localization of brain tumors. However, the rapid advances 
of MRI, functional MRI, and magnetic resonance spectroscopy (MRS) spectroscopy in the 
last decade have allowed the diagnostic imaging of neurotumors combining the use of 
physiology-based imaging methods that complement the more traditional morphology-
based imaging protocols. For example, “High-resolution spectroscopic imaging may 
contribute to pre-therapeutic grading and characterization of gliomas, as can diffusion 
techniques. The latter also hold promise in predicting survival in malignant supratentorial 
astrocytoma and could help to define areas for biopsy. Both methods can differentiate 
recurrent tumour from radiation injury. Perfusion-weighted magnetic resonance techniques 
offer potential markers of tumour angiogenesis and capillary permeability, and correlate 
well with vascular endothelial growth factor expression in grade II and grade III tumours. 
Functional magnetic resonance imaging can assess whether surgical treatment is feasible 
and select patients for intraoperative cortical stimulation” (Lemont et al., 2007).  
Recently, use of the nanoparticles in the diagnosis and detection of cancers, including 
glioblastomas, has gained much impetus because of putative enhancement involving their 
applications in MRI (Bhushan et al., 2010; Cole et al., 2011). The advances in development of 
newer cancer imaging and therapies based on metallic nanoparticles may help in early 
detection of cancer and thus contribute to decreasing deaths due to cancer. Various cancer 
imaging and therapies based on use of metallic nanoparticles are at different stages of 
preclinical and clinical development. Nanoparticles composed of iron oxide nanoparticles, 
zinc oxide nanoparticles, gold nanoparticles, silver nanoparticles, and cerium oxide 
nanoparticles have tremendous potentials to be developed as novel diagnostic and 
therapeutic agents in cancer (Bhushan et al., 2010; Jain 2010). Furthermore, enhanced cancer 
biomarker and genetic mutation detection techniques would help in identifying individuals 
at high risk for developing cancer. In this context, multi-functional metallic nanoparticles 
show exciting therapeutic potentials and these are currently under development for cancer 
therapy to be clinically applied in the near future. Metallic nanoparticles can be engineered 
to enhance the efficacy of current diagnostic and imaging techniques in cancer (Bhushan et 
al., 2010). Clearly, with the explosive advances in the design and applications of new 
metallic nanoparticles, this application area in cancer diagnosis and assessment shows 
exciting new potentials.  
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Technological advances that can be exploited to treat glioblastoma: As already alluded to 
above, the recent “renaissance of the Warburg Hypothesis” has stimulated much research 
into cancer cell metabolism (Bhardwaj et al., 2010; Lino & Merlo, 2009; Ordys et al., 2010; 
Semenza, 2011; Stegh et al., 2008). Indeed, the presumed dependence of cancer cells on 
glycolysis for cancer cell growth and proliferation has prompted much new investigation 
into exploring the glycolytic pathway as a new target for anti-cancer drug discovery 
(Bhardwaj et al., 2010; Chatterji et al., 2007; Chatterji et al., 2009; Lai et al., 2008; Lino & 
Merlo, 2009). We have demonstrated that two glycolytic enzyme inhibitors, 3-
bromopyruvate and iodoacetate, showed efficacy in lowering the survival of pancreatic 
cancer (Bhardwaj et al., 2010) and glioblastoma U87 (Chatterji et al., 2007; Chatterji et al., 
2009; Lai et al., 2008) cells. Thus, our studies strongly suggest that glycolytic enzyme 
inhibitors exhibit proof-of-concept potential in discovering new anti-cancer drugs (Bhardwaj 
et al., 2010; Chatterji et al., 2007; Chatterji et al., 2009; Lai et al., 2008). Consistent with our 
findings (Bhardwaj et al., 2010; Chatterji et al., 2007; Chatterji et al., 2009; Lai et al., 2008) are 
the results of human clinical trials employing 2-deoxyglucose (2-DG) in combination 
therapy with radiation for treatment of glioma (Prasanna et al., 2009). An inhibitor of 
glucose transport and glycolysis, 2-DG reportedly enhances the effects of radiation in 
inducing glioma cell death (Prasanna et al., 2009). Thus, the glycolytic pathway in 
glioblastoma constitutes an excellent target for further anti-cancer drug discovery studies. 
Nevertheless, because the prognosis of patients diagnosed with glioblastoma is abysmal, 
there is an urgent need to more fully elucidate the metabolic phenotype of glioblastomas 
along with exploring glycolysis as a target for discovering new anti-cancer drugs.  
Magnetic resonance spectroscopy to elucidate metabolic adaptations/alterations in 
glioblastoma: High lactate accumulation, despite adequate oxygen availability, is a 
metabolic pattern commonly associated with malignant transformation of the uncontrolled 
dividing cell. This metabolic phenotype, termed aerobic glycolysis and historically known as 
the Warburg effect, is characterized by high glycolytic rates and reduced mitochondrial 
oxidation (Bhardwaj et al., 2010; Lino & Merlo, 2009; Ordys et al., 2010; Semenza, 2011; Stegh 
et al., 2008), features that favor cell survival in the hypoxic microenvironments found in 
tumors. This phenotype also favors the routing of key metabolic intermediates away from 
oxidative metabolism and toward anabolic processes required by rapidly dividing cells 
(McFate et al., 2008). However, the mechanistic relationship between altered glucose 
metabolism and malignancy remains poorly understood due to prior lack of appropriate 
techniques to study such phenomena. MRS has become a major tool in the non-invasive 
characterization of brain tumor metabolism in vivo and in vitro. A highly versatile technique, 
MRS allows measurements of the concentrations of many neurochemicals, including the 
kinetics of single enzyme-catalyzed reactions such as LDH (Xu et al., 2007) or creatine kinase 
(Smith et al., 1997), as well as the rates of entire metabolic pathways, such as the TCA cycle 
and the glutamate/glutamine neurotransmitter cycle (Sibson et al., 2001; de Graaf et al., 
2003). MRS is commonly employed with several stable (non-radioactive) isotopes of 
biological importance such as 1H, 13C, 15N, and 31P, allowing investigation of many aspects 
of cellular metabolism. Of these nuclei, only 1H and 31P exist at ~100% natural abundance, 
thus requiring no specific enrichment prior to their measurement. Because 13C exists at low 
natural abundance (~1.1%), selective enrichment of 13C in appropriate substrates allow its 
use as a metabolic tracer. The high chemical specificity of 13C MRS, which can distinguish 
13C isotope incorporation into not only different molecules, but also specific carbon positions 
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within the same compound, allows the fate of the 13C label into and through multiple 
metabolic pathways to be followed (Zwingmann and Leibfritz, 2003). Until recently the low 
sensitivity of 13C detection (and correspondingly large detection volume) has precluded its 
use for in vivo imaging of tumors, although with the advent of Dynamic Nuclear 
Polarization (DNP) and hyperpolarized biomarkers of tumor metabolism (see below), direct 
13C detection could become a major tool in tumor staging and response to targeted 
therapies.  
As discussed above, brain tumors such as gliomas produce increased amounts of lactate, 
which can be measured by 1H MRS (Kaibara et al., 1998; Herholz et al., 1992; Terpstra et al., 
1998; McKnight, 2004). Glucose production of lactate through glycolysis, whether produced 
anaerobically (hypoxia) or aerobically, can be determined from the change in lactate 
concentration verses time in a series of sequentially acquired 1H or 13C NMR spectra. Lactate 
can be measured either without isotopic labeling (e.g., by differencing of 1H spectra or by 
use of selective lactate-editing techniques), or with 13C isotopic enrichment of the precursor 
glucose pool, and both approaches have their specific advantages depending on the desired 
information. With 13C isotopic enrichment additional MRS techniques can be employed, 
such as direct 13C detection with 1H-decoupling to enhance sensitivity and resolution, or 
direct 1H detection with 13C-editing to differentiate 13C-labeled from unlabeled proton 
resonances, so-called heteronuclear 1H-[13C] MRS. Because the heteronuclear 13C-edited 1H 
differencing technique (Fitzpatrick et al., 1990) permits both labeled and unlabeled species 
to be measured from a single set of acquired spectra, the fractional enrichment of lactate-C3 
reflects the sum of the pathways contributing carbon atoms (both 13C and 12C) to the C3 
position of lactate.  
The use of heteronuclear 1H-[13C] MRS to characterize the C6 glioma metabolic phenotype 
(high glycolysis and low oxidation) was elegantly demonstrated for the rat brain in vivo by 
Terpstra et al., (1998). These authors found that the glioma metabolized glucose to lactate 
increased lactate turnover and reduced oxidative metabolism of glucose by the reduced 
incorporation of 13C label in glutamate, which is a measure of TCA cycle flux. 1H and 1H/13C 
heteronuclear MRS methods have also been used to study glioma biopsies ex vitro (Barton et 
al., 1999; Martínez-Bisbal et al., 2004) and glial-derived tumor cell lines in vitro (Portais et 
al., 1993; Serkova et al., 1996; Lehtimäki et al., 2003). In ongoing studies in our laboratory, 
we incubated cultured human glioblastoma U87 cells with [1,6-13C2]glucose as a tracer and 
measured the metabolite profiles in extracts of these cells using 1H-[13C] MRS (Fig. 1). The 
extract spectra revealed high levels of lactate, with lower levels of glutamate and alanine, as 
well as other substances not yet identified. Inspection of 13C labeled metabolites revealed 
substantial turnover of lactate-C3 (percentage enrichment, ~31%) compared to a lower 
enrichment in glutamate-C4 (~14%), consistent with a more glycolytic (and less oxidative) 
metabolic phenotype. The high glycolytic and low oxidative rates displayed by gliomas 
suggest these pathways as potential therapeutic targets, as emphasized in several reports 
(Mathupala et al., 2010). 
More recently, the introduction of hyperpolarized MRS, which increases the detection 
sensitivity of an NMR-active nucleus up to 10,000 times, has generated intense excitement in 
the possibility of imaging low concentration metabolites. Special techniques are employed to 
achieve hyperpolarization, although the lifetime is brief, decaying according to the spin-
lattice relaxation time. Thus, 13C in carbonyl groups, which exhibit long T1's (many tens of 
seconds) can be suitable employed as metabolic probes. Particularly promising as a 
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biomarker of tumor metabolism has been the development of hyperpolarized 13C-labeled 
substrates such as [1-13C]pyruvate (Kurhanewicz et al., 2011). Tumors express high amounts 
of LDH, which catalyzes a rapid exchange between pyruvate and lactate. The rapid 
appearance of hyperpolarized [1-13C]lactate can thus serve as an indirect measure of LDH 
activity and tumorgenicity. Additional metabolic products are seen, such as [1-13C]alanine, 
resulting from alanine transaminase, and H13CO3, arising through decarboxylation by 
pyruvate dehydrogenase and subsequent hydration by carbonic anhydrase. Reduced 
H13CO3 reflecting reduced TCA cycle flux can also be used as a biomarker of tumor 
mitochondrial metabolism (Terpstra et al., 1998). The method was recently applied to the 
study of human glioblastoma xenografts in rats (Park et al., 2010) and glioblastoma cells and 
murine xenografts in vitro and in vivo to follow the effects of an inhibitor (and anticancer 
agent) of phosphotidylinositol-3-kinase on tumor growth (Ward et al, 2010). For studies of 
brain tumors, hyperpolarized molecules such as [1-13C]pyruvate and other substrates may 
prove particularly useful because the blood-brain-barrier, which normally restricts the 
passage of substrates, is disturbed during tumor growth, allowing for faster uptake and 
more time for metabolism prior to the decay of polarization.  
 
 
Fig. 1. Representative in vitro 1H-[13C]-NMR spectra of extracts of U87 glioblastoma cell 
pellet after 30 min incubation of [1,6-13C2]glucose(10 mM): (A) Total metabolite intensity 
representing the sum of 12C and 13C; (B) 13C-labeled metabolites arising during [1,6-
13C2]glucose infusion (10 mM: 30 min incubation). Highlight (x6) areas of Glu and Ala 13C-
labeled metabolites. Abbreviations: Glu4, glutamate-C4; Ala-C3, alanine-C3 and Lac3, 
lactate-C3. Spectra were scaled independently to enhance visual clarity owing to the lower 
amino acid levels observed in U87 glioblastoma cell pellet.  
4.7 MicroRNA approach 
Gene expression can be regulated by microRNAs. MicroRNAs are 19-25 nucleotides long 
and are capable of inhibiting translation and mRNA degradation thereby blocking protein 
production. microRNAs are named by numbers and the number reflects the sequence when 
they are identified. The next microRNA discovered will be the next number. Also mature 
microRNAs are named as miR whereas the primary transcript is named as mir. They 
influence multiple processes in several diseases including cancer (Mendell, 2005). In cancer, 
their effects are found in invasion, migration and metastasis (Nana-Sinkam & Croce, 2011). 
They play roles as oncogenes and tumor suppressor genes in several cancer types. Each 
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miRNA can affect several genes and each gene can be regulated by several microRNAs. The 
relationship between the target RNA and microRNA in regulating many pathological states 
is emerging (Perron et al., 2007). Thus, it is timely to investigate the impact of microRNAs in 
glioblastoma invasion and migration and apply this knowledge in mapping cancer 
therapeutic strategies. An emerging role of microRNA in resistance may be attributed to its 
effect on MDR. MicroRNAs mR-27a, miR-451 and miR-138 are known to impact response to 
chemotherapeutic drugs in several cancers including esophageal, breast, and ovarian 
cancers and leukemia (Hing et al., 2010; Li et al., 2010; Zhao et al., 2010; Kovalchuk et al., 
2008). P-glycoprotein is present in the blood-brain barrier and may be regulated by miR-27a 
and miR451 (Zhu et al., 2008). In glioblastoma, 10 different miRNA were identified and 
shown to be predictor of prognosis (Srinivasan et al., 2011). In addition, miR-10b (Gabriely 
et al., 2011) has been implicated in progression of gliomas. MiR-101 that regulates PcG 
protein EZH2, a histone methyltransferase, may play a role in glioblastoma progression 
(Smits et al, 2010). Other microRNA’s implicated in glioblastoma progression are listed in 
Table 1. 
4.8 Isoflavones 
Micronutrients may be employed as chemopreventive agents: they may be employed to 
suppress or reverse carcinogenesis, thereby preventing the development of cancer. 
“Micronutrients include any dietary substance, essential or non-essential that are present in 
small amounts and brings about a physiological effect” (Greenwald et al., 2002). Example of 
micronutrients include, but are not limited to, vitamins, minerals, soy phytoestrogens, and 
other phytochemicals (Russo et al., 2005). Isoflavones are phytoestrogen compounds highly 
enriched in soy and exhibit anticancer properties. Epidemiological studies have 
demonstrated that Asian population consuming diets rich in isoflavones show lower 
incidences of hormone-related cancers (Lee et al., 1991). Genistein (4’, 5, 7-
trihydroxyisoflavone) and biochanin A (4’-methoxy, 5, 7-dihydroxy isoflavone) are natural 
isoflavonoid phytoestrogens and are found in soy and subterranean clover, respectively 
(Persky & Van Horn, 1995). Genistein is a well studied chemopreventive agent (Taylor et al., 
2009; Sarkar & Li, 2002). Genistein exerts its anti-cancer properties via several mechanisms: 
inhibition of tyrosine phosphorylation, weak estrogenic and anti-estrogenic properties, as an 
anti-oxidant, inhibition of topoisomerase II, inhibition of angiogenesis, and induction of cell 
differentiation in breast cancer cells (Barnes & Peterson, 1995; Fotsis et al., 1993; Messina et 
al., 1994). Genistein also competes with ATP for binding to the tyrosine kinase domain, 
thereby inhibiting tyrosine kinase-mediated signaling processes (Chen et al., 2003). Our 
work in an in vitro co-culture model showed genistein inhibits glioblastoma invasion by 
inhibiting EGFR tyrosine kinase activity (Penar et al., 1997; Penar et al., 1998). Biochanin A 
has inhibitory potential on lung tumor development in mice induced by benzo(a)pyrene 
(Lee et al., 1991). Both genistein and biochanin A inhibit serum- and EGF-stimulated growth 
of human prostate cancer cells (Peterson & Barnes, 1993; Hempstcok et al., 1998). Biochanin 
A also inhibits the incidence and growth of xenograft tumors in athymic mice subsequent to 
injection of prostate cancer cells (LNCap) into the mice (Rice et al., 2002). We have 
demonstrated that both genistein and biochanin A inhibit invasion of glioblastoma cells by 
lowering the expression and activity of matrix-degrading enzymes (Puli et al., 2006). Soy 
isoflavones appear to be safe and effective in pre-clinical studies but clinical trials 
supporting their efficacy are still required (Virk-Baker et al., 2010). 
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MICRO 
RNA 
FUNCTIONAL EFFECTS REFERENCES 
miR-7 EGFR, Akt pathway Kefas et al., 2008 
miR-10b Resistance, Invasion Ujifuku et al., 2010; Sasayama et al.,
2009 
miR-21 Apoptosis, EGFR, Tumor suppressor,
MMP, Resistance 
Shi et al., 2010; Ren et al., 2010; Zhou et
al., 2010; Li et al., 2009;  
Conti et al., 2009; Chen et al., 2008;
Papagiannakopoulos et al., 2008;  
Gabriely et al., 2008; corsten et al., 2007;
Chan et al., 2005 
miR-34a Oncogenes Li et al., 2009; Li et al., 2009 
miR-93 Angiogenesis, tumor growth Fang et al., 2011 
miR-124a Migration, Invasion Fowler et al., 2011; Silber et al., 2008 
miR125a Invasion  Cortez et al., 2010 
miR-128 Oncogenes, Stem cell renewal factor Godlewski et al., 2008 
miR-137 Differentiation Silber et al., 2008 
miR-146b-
5p 
EGFR, Migration, Invasion Fowler et al., 2011; Xia et al., 2009 
miR-153 Apoptosis Xu et al., 2010; Xu et al., 2011 
miR-181 Resistance Slaby et al., 2010 
miR-181a Radiosensitivity Chen et al., 2010 
miR-181b Proliferation Conti et al., 2009 
miR-195 Resistance Ujifuku et al., 2010 
miR-196 Prognosis Guan et al., 2010 
miR-
221/222 
P27(kip) survivin, radiosensitivity,
PUMA 
Wang et al., 2011; Zhang CZ et al., 2010;
Zhang C et al., 2009;  
Lorimer, 2009; Zhang et al., 2009; Conti
et al., 2009;  
Lukiw et al., 2009; Gillies & Lorimer,
2007 
miR-326 Pyurvate kinase M2 Kefas et al., 2010 
miR-328 ABCG2 expression, resistance Li et al., 2010 
miR-451 Tumor suppressor, proliferation,
migration, resistance, metabolic stress 
Nan et al,2010; Godlewski et al., 2010;
Godlewski et al., 2010;  
Gal et al., 2008 
miR-455-3p Resistance Ujifuku et al., 2010 
Table 1. MicroRNA implicated in Glioblastoma Progression and Treatment 
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4.9 Implications of targeting the blood-brain barrier in developing novel approaches 
Targeting drugs that cross the blood-brain barrier (BBB) to reach the 
extracellular/interstitial space (ECS) in brain post formidable challenges because the 
capillary endothelial cells are lined with intercellular tight junctions that restrict transfer of 
molecules from blood to the ECS (Lino & Merlo, 2009; Patel et al., 2009; Redzic, 2011). 
Moreover, the capillary endothelium on the brain side is completely surrounded or 
wrapped by astroglial end feet (Patel et al., 2009; Redzic, 2011). Several strategies have been 
proposed to deal with the restrictions of the BBB. Such strategies include: chemically 
modified delivery systems; biologically assisted delivery systems; disruption of the BBB; use 
of molecular Trojan horses such as peptidomimetic monoclonal antibodies; and particulate 
drug carrier systems (Juillerat-Jeanneret , 2008; Patel et al., 2009). Nevertheless, among these 
strategies, which are particularly suitable for delivering drugs to target glioblastomas 
remain to be definitively ascertained. Glioblastomas are cancer cells that exhibit diverse 
genotypic and phenotypic characteristics that allow them to adapt to their 
microenvironment so as to facilitate their proliferation and invasion into the surrounding 
normal brain tissue (see Lino & Merlo, 2009 and references therein). Consequently, further 
research is needed to combine a realistic assessment of their genotypic and phenotypic 
characteristics and how they adapt to their intracerebral niche along with selecting the 
appropriate strategy to target the desired efficacious chemotherapeutic agent to such 
gliomas. For example, on the one hand, around low-grade gliomas, the BBB is intact and 
usually restrictive to drug penetration; on the other hand, around high-grade, more 
malignant gliomas, the BBB becomes leaky as a result of the tumors actively secreting 
proteases and other factors that can actively degrade the tight junctions between the 
endothelial cells at their vicinity (Lino & Merlo, 2009). However, as the tumor grows 
aggressively, an increasing pressure in the ECS is being built up, ultimately leading to 
capillary and venous collapse. Consequently, any strategizing in optimizing the delivery of 
chemotherapeutic agents to the gliomas will have to consider the physiological and/or 
pathophysiological status of the capillaries that deliver oxygen and nutrients to the gliomas.  
5. Conclusions 
Several new approaches have been developed to treat glioblastomas during the last two 
decades. However, these approaches have not resulted in lowering the mortality and 
morbidity of patients suffering from this disease. The reason for this therapeutic inadequacy 
is that we are dealing with a tumor with highly malignant character and that the presence of 
the blood-brain barrier precludes easy access for drugs to target to the tumor. We have 
discussed the progress in understanding the aggressive phenotypic characteristics of 
glioblastomas and identified multiple drug targets (including key cell signaling and invasive 
processes) for treatment of this devastating disease. We have also emphasized the 
importance and the need to fully elucidate metabolic adaptive characteristics of 
glioblastoma employing the versatile new techniques involving nuclear magnetic resonance 
spectroscopy and imaging. Additionally, we have highlighted the use of new technologies 
whereby the restrictions of the blood-brain barrier to drug targeting can be circumvented. 
We included a brief review of some new roles of micro-RNAs in glioblastoma progression 
and treatment and showed their potential in mapping new strategies in treating 
glioblastomas. Ultimately, a successful strategy in treating glioblastomas leading to 
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improved patient outcome and survival necessarily involves a combination of drug targets 
based on a deeper appreciation of the metabolic adaptations of glioblastomas.  
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